Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

Institute of Liver and Biliary Sciences, India

Status

Withdrawn

Conditions

Hepatocellular Carcinoma With Portal Vein Thrombosis

Treatments

Procedure: Endoscopic Variceal Ligation

Drug: Carvedilol

Study type

Interventional

Funder types

Other

Identifiers

NCT01659346

ILBS-HCC-01

Details and patient eligibility

About

Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients of cirrhosis with Hepatocellular carcinoma and portal vein thrombosis
Presence of large oesophageal varices or small with high risk

Exclusion criteria

Any contra-indication to beta-blockers
Any Endoscopic Variceal Ligation or Sclerotherapy within last 3 months
High risk gastric varices
Any past history of Transhepatic Intrajugular Portosystemic Shunt or surgery for portal hypertension
Significant cardio or pulmonary co-morbidity
Any extrahepatic malignancy
Patients with past history of variceal bleed
Patients with non-tumor portal vein thrombosis
Refusal to participate in the study